Advertisement

Myoclonus

  • Steven E. LoEmail author
  • Steven J. Frucht
Chapter
  • 1.2k Downloads
Part of the Current Clinical Neurology book series (CCNEU)

Abstract

Myoclonus is defined as sudden, brief, nonsustained involuntary jerks [1]. Often described as “lightning-like” or “shock-like,” the speed of myoclonus separates it from other hyperkinetic movements. Myoclonus is a clinical sign resulting from abnormal neuronal activation, which leads to either muscle contraction (positive myoclonus) or the inhibition of muscle contractions (negative myoclonus). The differential diagnosis of myoclonus is broad, and therefore, a careful investigation of underlying sources is required.

Keywords

Deep Brain Stimulation Video Segment Myoclonic Epilepsy Sodium Oxybate Myoclonic Jerk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Supplementary material

CASES 1-15: Myoclonus (wmv 107,369 KB)

References

  1. 1.
    Marsden CD, Hallett M, Fahn S. The nosology and pathophysiology of myoclonus. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterwork Scientific; 1982. p. 196–248.Google Scholar
  2. 2.
    Hallett M. Early history of myoclonus. Adv Neurol. 1986;43:7–10.PubMedGoogle Scholar
  3. 3.
    Goetz CG, Chmura TA, Lanska DJ. History of myoclonus: part 8 of the MDS-sponsored history of movement disorders exhibit, Barcelona, June 2000. Mov Disord. 2001;16:545–7.PubMedGoogle Scholar
  4. 4.
    Friedreich N. Neuropathologische Beobachtung beim paramyoklonus multiplex. Virch Arch Pathol Anat Physiol Klin Med. 1881;86:421–34.Google Scholar
  5. 5.
    Caviness JN. Epidemiology of myoclonus. Adv Neurol. 2002;89:19–22.PubMedGoogle Scholar
  6. 6.
    Aigner BR, Mulder DW. Myoclonus: clinical significance and an approach to classification. Arch Neurol. 1960;2:600–15.PubMedGoogle Scholar
  7. 7.
    Swanson PD, Luttrell CN, Magladery JW. Myoclonus: a report of 67 cases and review of the literature. Medicine. 1962;41:339–56.PubMedGoogle Scholar
  8. 8.
    Caviness JN, Alving LI, Maraganore DM, et al. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc. 1999;74:565–9.PubMedGoogle Scholar
  9. 9.
    Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol. 2004;3:598–607.PubMedGoogle Scholar
  10. 10.
    Gasser T. Inherited myoclonus-dystonia syndrome. Adv Neurol. 1998;78:325–34.PubMedGoogle Scholar
  11. 11.
    Gerrits MCF, Foncke EMJ, de Haan R, et al. Phenotype-genotype correlation in Dutch patients with myoclonus-dystonia. Neurology. 2006;66:759–61.PubMedGoogle Scholar
  12. 12.
    Fahn S, Marsden CD, Van Woert MH. Definition and classification of myoclonus. Adv Neurol. 1986;43:1–6.PubMedGoogle Scholar
  13. 13.
    Fahn S, Singh N. An oscillating form of essential myoclonus. Neurology. 1981;31:80.Google Scholar
  14. 14.
    Frucht SJ. The clinical challenge of posthypoxic myoclonus. Adv Neurol. 2002;89:85–8.PubMedGoogle Scholar
  15. 15.
    Agarwal P, Frucht SJ. Myoclonus. Curr Opin Neurol. 2003;16:515–21.PubMedGoogle Scholar
  16. 16.
    McKeon A, Pittock S, Matsumoto J, et al. Whole-body tremulousness syndrome: generalized small-amplitude polymyoclonus [Abstract]. Neurology. 2007;68 Suppl 1:A159.Google Scholar
  17. 17.
    Shibasaki H, Hallett M. Electrophysiological studies of myoclonus. Muscle Nerve. 2005;31:157–74.PubMedGoogle Scholar
  18. 18.
    Blindauer KA. Myoclonus. Continuum: lifelong learning in neurology. Mov Disord. 2004;10:174–88.Google Scholar
  19. 19.
    Brown P. Myoclonus. Curr Opin Neurol. 1996;9:314–6.PubMedGoogle Scholar
  20. 20.
    Quinn NP, Rothwell JC, Thomson PD, et al. Hereditary myoclonic dystonia, hereditary torsion dystonia and hereditary essential myoclonus: an area of confusion. Adv Neurol. 1988;50:391–401.PubMedGoogle Scholar
  21. 21.
    Pranzatelli MR. Serotonin and human myoclonus. Rationale for the use of serotonin receptor agonists and antagonists. Arch Neurol. 1994;51:605–17.PubMedGoogle Scholar
  22. 22.
    Lhermitte F, Peterfalvi M, Marteau R, et al. Analyse pharmacologique d’un cas de myoclonies d’intention et d’action postanoxiques. Rev Neurol (Paris). 1971;124:21–31.Google Scholar
  23. 23.
    Giménez-Roldán S, Mateo D, Muradas V, et al. Clinical, biochemical, and pharmacological observation in a patient with postasphyxic myoclonus: association to serotonin hyperactivity. Clin Neuropharmacol. 1988;11:151–60.PubMedGoogle Scholar
  24. 24.
    Giménez-Roldán S. Neuropharmacology and treatment of myoclonus. In: Jankovic JJ, Tolosa E, editors. Parkinson’s disease and movement disorders. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 301–10.Google Scholar
  25. 25.
    Lauterbach EC. Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick’s disease. Mov Disord. 1994;9:343–6.PubMedGoogle Scholar
  26. 26.
    Bharucha KJ, Sethi KD. Complex movement disorders induced by fluoxetine. Mov Disord. 1996;11:324–6.PubMedGoogle Scholar
  27. 27.
    Ghika-Schmid F, Ghika J, Vuadens P, et al. Acute reversible myoclonic encephalopathy associated with fluoxetine therapy. Mov Disord. 1997;12:622–3.PubMedGoogle Scholar
  28. 28.
    Matsumoto RR. Involvement of gamma-aminobutyric acid in myoclonus. Adv Neurol. 2002;89:249–62.PubMedGoogle Scholar
  29. 29.
    Enna SJ, Ferkany JW, Van Woert M, et al. Measurement of GABA in biological fluids: effect of GABA transaminase inhibitors. Adv Neurol. 1979;23:741–50.Google Scholar
  30. 30.
    Rothwell JC. Pathophysiology of spinal myoclonus. Adv Neurol. 2002;89:137–44.PubMedGoogle Scholar
  31. 31.
    Brown P, Thompson P. Electrophysiological aids to the diagnosis of psychogenic jerks, spasms, and tremor. Mov Disord. 2001;16:595–9.PubMedGoogle Scholar
  32. 32.
    Frucht SJ, Leurgans SE, Hallett M, et al. The Unified Myoclonus Rating Scale. Adv Neurol. 2002;89:361–76.PubMedGoogle Scholar
  33. 33.
    Brown P, Day BL, Rothwell JC, et al. Intrahemispheric and interhemispheric spread of cerebral cortical myoclonic activity and its relevance to epilepsy. Brain. 1991;114:2333–51.PubMedGoogle Scholar
  34. 34.
    Brown P, Ridding MC, Werhahn KJ, et al. Abnormalities of the balance between inhibition and excitation in the motor cortex of patients with cortical myoclonus. Brain. 1996;119:309–17.PubMedGoogle Scholar
  35. 35.
    Obeso JA, Zamarbide I. Classification, clinical features, and treatment of myoclonus. In: Watts RL, Koller WC, editors. Movement disorders: neurologic principles and practice. 2nd ed. New York: McGraw-Hill; 2004. p. 659–69.Google Scholar
  36. 36.
    Hallett M, Chadwick D, Adam J, et al. Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry. 1977;40:253–64.PubMedGoogle Scholar
  37. 37.
    Fox EJ, Villanueva R, Schutta HS. Myoclonus following spinal anesthesia. Neurology. 1979;29:379–80.PubMedGoogle Scholar
  38. 38.
    Levy R, Plassche W, Riggs J, et al. Spinal myoclonus related to an arteriovenous malformation. Response to clonazepam therapy. Arch Neurol. 1983;40:254–5.PubMedGoogle Scholar
  39. 39.
    Davis SM, Murray NM, Diegdoh JV, et al. Stimulus-sensitive spinal myoclonus. J Neurol Neurosurg Psychiatry. 1981;44:884–8.PubMedGoogle Scholar
  40. 40.
    Garcin R, Rondot P, Guiot G. Rhythmic myoclonus of the right arm as the presenting symptom of a cervical cord tumour. Brain. 1968;91:75–84.PubMedGoogle Scholar
  41. 41.
    Jankovic J, Pardo R. Segmental myoclonus: clinical and pharmacologic study. Arch Neurol. 1986;43:1025–31.PubMedGoogle Scholar
  42. 42.
    Lagueny A, Tison F, Burbaud P, et al. Stimulus-sensitive spinal myoclonus improved with injections of botulinum toxin type A. Mov Disord. 1999;14:182–5.PubMedGoogle Scholar
  43. 43.
    Neshige R, Kuroda Y, Oda K, et al. Reflex spinal myoclonus. Report of a case and its physiologic mechanism. Rinsho Shinkeigaku. 1985;25:408–11.PubMedGoogle Scholar
  44. 44.
    Shivapour E, Teasdall RD. Spinal myoclonus with vacuolar degeneration of anterior horn cells. Arch Neurol. 1980;37:451–3.PubMedGoogle Scholar
  45. 45.
    Roobol TH, Kazzaz BA, Vecht CJ. Segmental rigidity and spinal myoclonus as a paraneoplastic syndrome. J Neurol Neurosurg Psychiatry. 1987;50:628–31.PubMedGoogle Scholar
  46. 46.
    Keswani SC, Kossoff EH, Krauss GL, et al. Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry. 2002;73:457–8.PubMedGoogle Scholar
  47. 47.
    Siniscalchi A, Mancuso F, Russo E, et al. Spinal myoclonus responsive to topiramate. Mov Disord. 2004;19:1380–1.PubMedGoogle Scholar
  48. 48.
    Chokroverty S. Propriospinal myoclonus. Clin Neurosci. 1995–1996;3:219–22.Google Scholar
  49. 49.
    Bussel B, Roby BA, Azouvi P, et al. Myoclonus in a patient with spinal cord transaction. Possible involvement of the spinal stepping generator. Brain. 1988;111:1235–45.PubMedGoogle Scholar
  50. 50.
    Brown P, Thompson PD, Rothwell JC, et al. Axial myoclonus of propriospinal origin. Brain. 1991;114:197–214.PubMedGoogle Scholar
  51. 51.
    Brown P, Rothwell JC, Thompson PD, et al. Propriospinal myoclonus: evidence for spinal “pattern” generators in humans. Mov Disord. 1994;9:571–6.PubMedGoogle Scholar
  52. 52.
    Manconi M, Sferrazza B, Iannaccone S, et al. Case of symptomatic propriospinal myoclonus evolving toward acute “myoclonic status”. Mov Disord. 2005;20:1646–50.PubMedGoogle Scholar
  53. 53.
    Shibasaki H. Pathophysiology of negative myoclonus and asterixis. Adv Neurol. 1995;67:199–209.PubMedGoogle Scholar
  54. 54.
    Adams RD, Foley JM. The neurological changes in the more common types of severe liver disease. Trans Am Neurol Assoc. 1949;74:217–9.Google Scholar
  55. 55.
    Obeso JA, Artieda J, Burleigh A. Clinical aspects of negative myoclonus. Adv Neurol. 1996;67:1–8.Google Scholar
  56. 56.
    Lance JW, Adams RD. The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain. 1963;86:111–36.PubMedGoogle Scholar
  57. 57.
    Frucht SJ, Trost M, Ma Y, et al. The metabolic topography of posthypoxic myoclonus. Neurology. 2004;62:1879–81.PubMedGoogle Scholar
  58. 58.
    Werhahn KJ, Brown P, Thompson PD, et al. The clinical features and prognosis of chronic posthypoxic myoclonus. Mov Disord. 1997;12:216–20.PubMedGoogle Scholar
  59. 59.
    Frucht S, Fahn S. The clinical spectrum of posthypoxic myoclonus. Mov Disord. 2000;15 Suppl 1:2–7.PubMedGoogle Scholar
  60. 60.
    Krauss GL, Bergin A, Kramer RE, et al. Suppression of posthypoxic and post-encephalitic myoclonus with levetiracetam. Neurology. 2001;56:411–2.PubMedGoogle Scholar
  61. 61.
    Frucht SJ, Louis ED, Chuang C, et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology. 2001;57:1112–4.PubMedGoogle Scholar
  62. 62.
    Schauer R, Singer M, Saltuari L, et al. Suppresion of cortical myoclonus by levetiracetam. Mov Disord. 2002;17:411–5.PubMedGoogle Scholar
  63. 63.
    Frucht SJ, Bordelon Y, Houghton WH. Marked amelioration of alcohol-responsive posthypoxic myoclonus by γ-hydroxybutyric acid (Xyrem). Mov Disord. 2005;20:745–51.PubMedGoogle Scholar
  64. 64.
    Frucht SJ, Bordelon Y, Houghton WH, et al. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord. 2005;20:1330–7.PubMedGoogle Scholar
  65. 65.
    Frucht SJ, Houghton WC, Bordelon Y, et al. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology. 2005;65:1967–70.PubMedGoogle Scholar
  66. 66.
    Fodstad H, Nilsson S. Intractable singultus: a diagnostic and therapeutic challenge. Br J Neurosurg. 1993;7:255–60.PubMedGoogle Scholar
  67. 67.
    Takahashi T, Murata T, Omori M, et al. Successful treatment of intractable hiccups with serotonin (5-HTP)1A receptor agonist. J Neurol. 2004;251:486–7.PubMedGoogle Scholar
  68. 68.
    Sanchack KE. Hiccups: when the diaphragm attacks. J Palliative Med. 2004;7:870–3.Google Scholar
  69. 69.
    Sharma P, Morgan JC, Sethi KD. Hiccups associated with dopamine agonists in Parkinson disease. Neurology. 2006;66:774.PubMedGoogle Scholar
  70. 70.
    Deuschl G, Mischke G, Schenck E, et al. Symptomatic and essential rhythmic palatal myoclonus. Brain. 1990;113:1645–72.PubMedGoogle Scholar
  71. 71.
    Deuschl G, Wilms H. Palatal tremor: the clinical spectrum and physiology of a rhythmic movement disorder. Adv Neurol. 2002;89:115–30.PubMedGoogle Scholar
  72. 72.
    Ross S, Jankovic J. Palatal myoclonus: an unusual presentation. Mov Disord. 2005;20:1200–2.PubMedGoogle Scholar
  73. 73.
    Sakai T, Oishi H. Olivary hypertrophy and palatal myoclonus. Arch Neurol. 2004;61:1965.PubMedGoogle Scholar
  74. 74.
    Jabbari B, Scherokman B, Gunderson CH, et al. Treatment of movement disorders with trihexyphenidyl. Mov Disord. 1989;4:202–12.PubMedGoogle Scholar
  75. 75.
    Nasr A, Brown N. Palatal myoclonus responding to lamotrigine. Seizure. 2002;11:136–7.PubMedGoogle Scholar
  76. 76.
    Scott BL, Evans RW, Jankovic J. Treatment of palatal myoclonus with sumatriptan. Mov Disord. 1996;11:748–51.PubMedGoogle Scholar
  77. 77.
    Jankovic J, Scott BL, Evans RW. Treatment of palatal myoclonus with sumatriptan. Mov Disord. 1997;12:818.PubMedGoogle Scholar
  78. 78.
    Pakiam AS, Lang AE. Essential palatal tremor: evidence of heterogeneity based on clinical features and response to sumatriptan. Mov Disord. 1999;14:179–80.PubMedGoogle Scholar
  79. 79.
    Deuschl G, Lohle E, Heinen F, et al. Ear click in palatal tremors: its origin and treatment with botulinum toxin. Neurology. 1991;41:1677–9.PubMedGoogle Scholar
  80. 80.
    Saeed SR, Brookes GB. The use of clostridium botulinum toxin in palatal myoclonus. A preliminary report. J Laryngol Otol. 1993;107:208–10.PubMedGoogle Scholar
  81. 81.
    Varney SM, Demetroulakos JL, Fletcher MH, et al. Palatal myoclonus: treatment with Clostridium botulinum toxin injection. Otolaryngol Head Neck Surg. 1996;114:317–20.PubMedGoogle Scholar
  82. 82.
    Penney SE, Bruce IA, Saeed SR. Botulinum toxin is effective and safe for palatal tremor. A report of five cases and a review of the literature. J Neurol. 2006;253:857–60.PubMedGoogle Scholar
  83. 83.
    Valente EM, Edwards MJ, Mir P, et al. The epsilon-sarcoglycan gene in myoclonic syndromes. Neurology. 2005;64:737–9.PubMedGoogle Scholar
  84. 84.
    Doheny DO, Brin MF, Morrison CE, et al. Phenotypic features of myoclonus-dystonia in three kindreds. Neurology. 2002;59:1187–96.PubMedGoogle Scholar
  85. 85.
    Asmus F, Gasser T. Inherited myoclonus-dystonia. Adv Neurol. 2004;94:113–9.PubMedGoogle Scholar
  86. 86.
    Nygaard TG, Raymond D, Chen C, et al. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol. 1999;46:794–8.PubMedGoogle Scholar
  87. 87.
    Zimprich A, Grabowski M, Asmus F, et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet. 2001;29:66–9.PubMedGoogle Scholar
  88. 88.
    Asmus F, Salih F, Hjermind LE, et al. Myoclonus-dystonia due to genomic deletions in the epsilon-sarcoglycan gene. Ann Neurol. 2005;58:792–7.PubMedGoogle Scholar
  89. 89.
    Grimes DA, Han F, Lang AE, et al. A novel locus for inherited myoclonus-dystonia on 18p11. Neurology. 2002;59:1183–6.PubMedGoogle Scholar
  90. 90.
    Han F, Lang AE, Racacho K, et al. Mutations in the epsilon-sarcoglycan gene found to be uncommon in seven myoclonus-dystonia families. Neurology. 2003;61:244–6.PubMedGoogle Scholar
  91. 91.
    Valente EM, Misbahuddin A, Brancati F, et al. Analysis of the epsilon-sarcoglycan gene in familial and sporadic myoclonus-dystonia: evidence for genetic heterogeneity. Mov Disord. 2003;18:1047–51.PubMedGoogle Scholar
  92. 92.
    Magariños-Ascone CM, Regidor I, Martinez-Castrillo JC, et al. Pallidal stimulation relieves myoclonus-dystonia syndrome. J Neurol Neurosurg Psychiatry. 2005;76:989–91.PubMedGoogle Scholar
  93. 93.
    Cif L, Valente EM, Hemm S, et al. Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord. 2004;19:724–7.PubMedGoogle Scholar
  94. 94.
    Priori A, Bertolasi L, Presenti A, et al. γ-Hydroxybutyric acid for alcohol-sensitive myoclonus with dystonia. Neurology. 2000;54:1706.PubMedGoogle Scholar
  95. 95.
    Kupsch A, Trottenberg T, Wassilios M, et al. Neurostimulation of the ventral intermediate thalamic nucleus alleviates hereditary essential myoclonus. J Neurol Neurosurg Psychiatry. 1999;67:415–6.PubMedGoogle Scholar
  96. 96.
    Fukuhara N, Tokiguchi S, Shirakawa K, et al. Myoclonus epilepsy associated with ragged-red fibers (mitochondrial abnormalities): disease entity or a syndrome? J Neurol Sci. 1980;47:117–33.PubMedGoogle Scholar
  97. 97.
    Tsairis P, Engel WK, Kark P. Familial myoclonic epilepsy syndrome associated with skeletal muscle mitochondrial abnormalities. Neurology. 1973;23:408.Google Scholar
  98. 98.
    DiMauro S, Hirano M, Kaufmann P, et al. Clinical features and genetics of myoclonic epilepsy with ragged red fibers. Adv Neurol. 2002;89:217–29.PubMedGoogle Scholar
  99. 99.
    Iwanga K, Mori K, Inoue M, et al. [Myoclonus epilepsy associated with ragged-red fibers–report of a patient with negative myoclonus]. Rinsho Shinkeigaku. 1992;32:870–3.PubMedGoogle Scholar
  100. 100.
    Thompson PD, Hammans SR, Harding AE. Cortical reflex myoclonus in patients with the mitochondrial DNA transfer RNA(Lys)(8344) (MERRF) mutation. J Neurol. 1994;241:335–40.PubMedGoogle Scholar
  101. 101.
    Mancuso M, Galli R, Pizzanelli C, et al. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci. 2006;243:97–9.PubMedGoogle Scholar
  102. 102.
    Crest C, Dupont S, Leguern E, et al. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology. 2004;62:640–3.PubMedGoogle Scholar
  103. 103.
    Lim LL, Ahmed A. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord. 2005;11:135–7.PubMedGoogle Scholar
  104. 104.
    Saitoh S, Kohsaka S, Mizukami S, et al. Cortical reflex myoclonus associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS): a case report. Brain Dev. 1992;14:260–3.PubMedGoogle Scholar
  105. 105.
    Thambisetty M, Newman NJ, Glass JD, et al. A practical approach to the diagnosis and management of MELAS: case report and review. Neurologist. 2002;8:302–12.PubMedGoogle Scholar
  106. 106.
    Monday K, Jankovic J. Psychogenic myoclonus. Neurology. 1993;43:349–52.PubMedGoogle Scholar
  107. 107.
    Samuel M, Kleiner-Fisman G, Lang AE. Voluntary control and a wider clinical spectrum of essential palatal tremor. Mov Disord. 2004;19:717–9.PubMedGoogle Scholar
  108. 108.
    Striano P, Manganelli F, Boccella P, et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiologic study. Mov Disord. 2005;12:1610–4.Google Scholar
  109. 109.
    Terwinghe G, Daumerie J, Nicaise C, et al. Therapeutic effects of piracetam in a case of posthypoxic action myoclonus (author’s transl). Acta Neurol Belg. 1978;78:30–6.PubMedGoogle Scholar
  110. 110.
    Ikeda A, Shibasaki H, Tashiro K, et al. Clinical trial of piracetam in patients with myoclonus: nationwide multi-institution study in Japan. Mov Disord. 1996;11:691–700.PubMedGoogle Scholar
  111. 111.
    Koskiniemi M, Van Vleyemen B, Hakamies L, et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multi-center, randomized, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry. 1998;64:344–8.PubMedGoogle Scholar
  112. 112.
    Pranzatelli MR. The pharmacology of antimyoclonic drugs. Clin Neurosci. 1995–1996;3:246–52.Google Scholar
  113. 113.
    Van Vleymen B, Van Zandijcke M. Piracetam in the treatment of myoclonus: an overview. Acta Neurol Belg. 1996;96:270–80.PubMedGoogle Scholar
  114. 114.
    Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res. 1998;29:109–14.PubMedGoogle Scholar
  115. 115.
    Yoshimura I, Kaneko S, Yoshimura N, et al. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res. 2001;46:283–7.PubMedGoogle Scholar
  116. 116.
    Fuller DE, Homfeldt CS, Kelloway JS, et al. The Xyrem risk management program. Drug Saf. 2004;27:293–306.PubMedGoogle Scholar
  117. 117.
    Gordon MF. Toxin and drug-induced myoclonus. Adv Neurol. 2002;89:49–76.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Department of NeurologyGeorgetown University HospitalWashingtonUSA
  2. 2.Department of NeurologyMount Sinai Medical CenterNew YorkUSA

Personalised recommendations

Cite chapter

Buy options